A5066148213- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Spondyloarthritis Studies and Treatments
- Autoimmune and Inflammatory Disorders Research
- Systemic Sclerosis and Related Diseases
- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- T-cell and B-cell Immunology
- Lymphoma Diagnosis and Treatment
- Atherosclerosis and Cardiovascular Diseases
- Immunotherapy and Immune Responses
- Inflammatory Bowel Disease
- Tuberculosis Research and Epidemiology
- Chronic Disease Management Strategies
- Celiac Disease Research and Management
- Cardiac, Anesthesia and Surgical Outcomes
- Healthcare cost, quality, practices
- Immune Cell Function and Interaction
- COVID-19 and healthcare impacts
- Spine and Intervertebral Disc Pathology
- Folate and B Vitamins Research
- Drug-Induced Hepatotoxicity and Protection
University of Crete
2018-2024
University Hospital of Heraklion
2021-2024
Center for Rheumatology
2023
Objectives Classification criteria are biased towards classifying long-standing disease. We compared the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR)-2019, Systemic Lupus International Collaborating Clinics (SLICC)-2012 and ACR-1997 in an early (median 48 months) systemic lupus erythematosus (SLE) cohort. Methods Patients diagnosed with SLE (n=690) or control diseases (n=401). Sensitivity, specificity time-to-classification were calculated. Modified...
Background Characterisation of the long-term outcome patients with ‘difficult to treat’ (D2T) rheumatoid arthritis and factors contributing its evolution are unknown. Herein, we explored heterogeneity D2T outcome. Methods Patients included from a prospective single centre cohort study. The EULAR definition was applied. Longitudinal clustering functional status (modified Health Assessment Questionnaire (mHAQ)) disease activity (Disease Activity Score-28 (DAS28)) were assessed using...
Abatacept (CTLA4-Ig)—a monoclonal antibody which restricts T cell activation—is an effective treatment for rheumatoid arthritis (RA). Nevertheless, only 50% of RA patients attain clinical responses, while predictors response are rather limited. Herein, we aimed to investigate early biomarkers abatacept, based on a detailed immunological profiling peripheral blood (PB) cells and serum proteins. We applied flow cytometry proteomics analysis PB immune respectively, starting abatacept as the...
Abstract Background Rituximab is used for the treatment of active rheumatoid arthritis. In present study, we examined long-term flare risk and safety reduced doses rituximab. Patients-methods This was a prospective, observational, single-center study patients starting rituximab on standard dose (SD). Patients were switched to low (LD) (1 g every 6 months), based treating rheumatologist’s decision after having achieved sustained clinical responses, while rest continued During 60-month period,...
<h3>Background:</h3> Data regarding the adoption of treat-to-target (T2T) approach aiming at inactive disease (ID), or low activity (LDA) in axial (axSpA) and peripheral Spondyloarthritis (perSpA) real-world clinical practice is scarce. <h3>Objectives:</h3> Our aims were to assess level SpA patients practice, extent T2T strategy implementation reasons possible non-implementation. <h3>Methods:</h3> Cross-sectional study all consecutive with who visited outpatient department one-day infusions'...
Abatacept (CTLA4-Ig) &ndash; a monoclonal antibody which restricts T cell activation is an effective treatment for rheumatoid arthritis (RA). Herein, we aimed to investigate biomarkers of response abatacept. We performed detailed immunological profiling CTLA4-treated RA patients&rsquo; peripheral blood (PB) cells and sera using flow cytometry proteomics analysis, respectively. At 6 months treatment, 34.5% patients attained clinical response. Notably, baseline levels Th1 myeloid...
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by significant clinical heterogeneity with early diagnosis being major challenge, complicated the absence of formal diagnostic criteria. Instead, classification criteria have been developed to enable homogenous inclusion patients in trials, most commonly used those American College Rheumatology (ACR 1997) and Lupus International Collaborating Clinics Classification Criteria (SLICC 2012). These are widely...
Background The treatment of rheumatoid arthritis (RA) includes conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and biologic DMARDs (bDMARDs). RA is associated with an increased risk serious infections (SI) the use bDMARDs almost doubles this risk. SI can lead to sepsis, a life-threatening condition manifested by organ failure caused dysregulated host response pathogen. target pro-inflammatory cytokines which mediate inflammation cascade activated both in sepsis....
Abstract To characterize disease activity trajectories and compare long-term drug retention between rheumatoid (RA) spondylarthritis (SpA) patients initiating tumor necrosis factor inhibitor (TNFi) treatment (etanercept). Prospective observational study of RA, axial (AxSpA) peripheral SpA (PerSpA) etanercept during 2004–2020. Kaplan–Meier plots were used for comparisons multivariable Cox regression models predictors discontinuation. Long-term identified by latent class growth using DAS28-ESR...
New biologic and small molecule targeted agents have expanded the armamentarium of Spondyloarthritides (SpA), allowing more therapeutic options for patients who do not respond to therapy.The implementation treat-to-target (T2T) strategy with close monitoring frequent treatment adaptations targeting disease remission has been proposed as means prevent radiographic progression long-term adverse outcomes.In this project we will employ "University Crete Rheumatology Clinic Registry"...
<h3>Background:</h3> A joined EULAR/ACR initiative has proposed a new set of classification criteria for SLE based on weighted items and the use ANA as an entry criterion. <h3>Objectives:</h3> To compare diagnostic performance old against physician diagnosis in early cohort examine phenotypic prognostic differences among patients who are classified with criteria. <h3>Methods:</h3> Adult diagnosed by experienced physicians (n=690) or control diseases (n=301) during 2005-2016 followed-up at...
Background: SLE onset is preceded by a preclinical phase evidenced the presence of anti-nuclear and other autoantibodies (autoAbs), which however, have low predictive value for development clinical SLE. Objectives: To define subgroup autoAbs-positive individuals who are at high risk progression into integrating environmental, clinical/serological, genetic transcriptome data. Methods: A multicenter, across five European countries, inception cohort or first-degree relatives (FDRs) patients...
Background: The ACR-1997, SLICC-2012 and EULAR/ACR-2019 classification criteria have high sensitivity specificity for SLE, yet they classify non-overlapping groups of patients suggesting that can be supplemented with additional features to improve their diagnostic performance. Objectives: To identify non-criteria manifestations are significantly associated SLE in clinical practice used complement the existing sets criteria. Methods: Individual items from all three (ACR-1997, SLICC-2012,...
Background Early or pre-clinical forms of lupus encompass a broad range presentations, spanning from asymptomatic individuals with immunological abnormalities to autoantibodies and some features suggestive SLE who do not yet meet the classification criteria. Research on this topic could reveal predictive diagnostic biomarkers for at-risk progression SLE. Objectives To examine rate transition classified (ACR 1997 criteria) SLE, identify demographic clinical predictors. prospectively evaluate...
Background: Herein we aimed to characterize disease activity trajectories and compare long-term drug retention between rheumatoid (RA) spondylarthritis (SpA) patients on etanercept treatment.Methods: Prospective observational study of RA, axial (AxSpA) peripheral SpA (PerSpA) initiating during 2004-2020. Kaplan-Meier plots were used for comparisons multivariate Cox regression models predictors discontinuation. Long-term identified by latent class growth using DAS28-ESR or ASDAS-CRP as...
Background: Long-term observational studies of patients under biologic disease-modifying anti-rheumatic drug (bDMARD) therapies in routine clinical practice can provide us with important data regarding comorbidities, who are usually excluded from randomized controlled studies. Objectives: To study the impact comorbidities outcome (response and persistence to therapy) spondyloarthritis (SpA) receiving bDMARDs real-world practice. Methods: Prospective all start a bDMARD tertiary centre...
Background: There is limited information on the burden of comorbidities in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) real-world clinical practice its impact incidence serious adverse events (SAE) during biologic disease-modifying anti-rheumatic drug (bDMARD) therapy. Objectives: To evaluate number RA SpA initiating a bDMARD everyday to explore association occurrence SAE Methods: Prospective study all who start any treatment tertiary centre University Hospital. All...
Background: Difficult-to-treat rheumatoid arthritis (D2T RA) was recently defined by a EULAR study group (1) and, as disease category it is largely complicated and under-researched. Patient comorbidities may play significant role in the response to therapy with biologic disease-modifying antirheumatic drugs (bDMARDs) classification D2T RA. Objectives: To evaluate impact of [studied total Comorbidities Count (CC) rheumatic comorbidity index (RDCI)] on 6-month first bDMARD real-world clinical...